Angiotensin receptor blockers: impact on costs of care.
Direct and indirect costs related to the treatment of hypertension are estimated at nearly $60 billion annually. Short- and long-term costs of healthcare utilization and treatment are, therefore, important considerations in selection of antihypertensive therapy. Studies of patients with hypertension and type 2 diabetes have shown that treatment with angiotensin receptor blockers (ARBs) can reduce healthcare costs as a result of a decreased incidence of end-stage renal disease and other clinical end points. ARBs also increase survival in these patients. Cost savings have also been reported in patients with heart failure as a result of reductions in office and emergency department visits, hospital admissions, and hospital stays.
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D017048:Health Care Costs / Q000706:statistics & numerical data; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics*; D007356:Insurance, Pharmaceutical Services / Q000191:economics / Q000706:statistics & numerical data; D014481:United States
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents